Trials / Completed
CompletedNCT02343172
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM201 | |
| DRUG | LEE011 |
Timeline
- Start date
- 2015-03-13
- Primary completion
- 2019-10-16
- Completion
- 2019-10-16
- First posted
- 2015-01-21
- Last updated
- 2020-12-09
Locations
9 sites across 6 countries: Canada, France, Germany, Singapore, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02343172. Inclusion in this directory is not an endorsement.